Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.45 |
| ▸ | CYSLTR2 | Q9NS75 | 2/20 | 0.45 |
| ▸ | CYSLTR1 | Q9Y271 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | MME | P08473 | 1/20 | 0.41 |
| ▸ | ACE | P12821 | 1/20 | 0.41 |
| ▸ | CPA1 | P15085 | 1/20 | 0.41 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.41 |
| ▸ | BCHE | P06276 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL320945 | 0.85 | TAAR1 (0.51) | TAAR1LMNAMAOB | |
| SCHEMBL22631755 | 0.84 | KMT2A (0.46) | TAAR1LMNASIGMAR1 | |
| SCHEMBL25146488 | 0.82 | GABRA1 (0.40) | TAAR1CYSLTR2CYSLTR1LMNASLC6A2 | |
| SCHEMBL321092 | 0.82 | MAOB (0.62) | MAOAMAOBMMEACECPA1 | |
| SCHEMBL10224054 | 0.82 | SIGMAR1 (0.51) | TAAR1SIGMAR1MAOBBCHE | |
| SCHEMBL14533963 | 0.81 | REN (0.48) | TAAR1CYSLTR2CYSLTR1 | |
| SCHEMBL8174800 | 0.78 | CETP (0.54) | TAAR1MMEACECPA1ACE2 | |
| SCHEMBL12281971 | 0.78 | TP53 (0.52) | TAAR1 | |
| SCHEMBL27832150 | 0.78 | TAAR1 (0.49) | TAAR1CYSLTR2CYSLTR1SLC6A2SIGMAR1 | |
| SCHEMBL9538055 | 0.76 | TAAR1 (0.56) | TAAR1MMEACECPA1ACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210107910-A1 | Compositions and Methods of Using the Same for Treatment of Neurodegenerative and Mitochondrial Disease | MITOKININ, INC. (US) | 2021-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210107910-A1 | Compositions and Methods of Using the Same for Treatment of Neurodegenerative and Mitochondrial Disease | NLN, NME4, COQ8A | TAAR1 3812/4885CYSLTR2 3191/4885CYSLTR1 3224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.